|Day Low/High||300.80 / 305.03|
|52 Wk Low/High||215.78 / 374.99|
Drug giants with money to spend and a friendlier regulatory environment should spur deals.
With weak chart patterns and a quantitative downgrade, longs should protect their positions.
The U.S. Food and Drug Administration approved the biotech company's treatment for spinal muscular atrophy late Friday.
My trade of the year for 2017 is to short the PowerShares QQQ Trust ETF , which tracks the Nasdaq 100 index. Here's my investment thesis for this play: The Nasdaq 100 Already Has Rallied QQQ already has risen from about $96 a share at the market's F...
Shoppers may want to wait until after the holidays for a bargain on BIIB.
Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.
The worst appears to be over for this sector; we could see big growth ahead.
Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.
The bullish side dominates, with consumer cyclicals and energy names most prevalent.
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
With the election resolved, biotech could be ripe for consolidation.
U.S. stocks rallied slightly in midday trading as energy, financials, and healthcare sectors saw green on Wednesday following the surprise election of Republican Donald Trump.
Shares of Biogen were higher on Monday after the biotech company and Ionis Pharmaceuticals said their Phase 3 trial of its spinal muscular atrophy drug met its primary endpoint.
U.S. stocks bounced around in the green in far more stable trading following three days of extreme swings.
Check out this biotech ETF, and Biogen, for plays on any recovery.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
Besides Tesla, Twitter and Biogen make good candidates.
RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.
Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.
Deal rumors are deflating, but a takeover bid could reward holdouts.
With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.
U.S. stocks hold near lows through to the end of the session as crude oil closes below $40 a barrel, its lowest level since April, on continued supply worries.
The companies were also the subject of merger rumors back in April.